Frailty is the statistical term for variation in risk due to factors that cannot be measured in individuals, including: inherited differences; environmental influences in utero, in childhood or in later life; and purely random somatic genetic or epigenetic events. In a hypothetical population where each individual has a constant risk of dying but people have different death-rates, the most susceptible will die younger and the average death rate of survivors will fall progressively. A conventional survival analysis shows the declining average death rate in the whole population, but an appropriate frailty model in which individuals have constant but different death rates fits the data equally well and estimates the range of variation in individual risk. Frailty retreats as biology advances, because by definition it involves unknown mechanisms and individual characteristics that are not yet measurable.
A major focus of the review on frailty by Aalen et al. The suggestion that this is the result of many genes with small effects acting in combination 5 was subsequently confirmed by genome-wide association studies, which have identified large numbers of inherited genetic variants that contribute to this polygenic variation in susceptibility to specific cancers and to many other diseases. Such variants usually have very small effects, often accounting for less than 1% of the overall familial variation, and for most diseases the combined effect of all known variants does not account for much of the familial variation. This realization drives the continuing search for the causes of this 'missing heritability'.
A variety of frailty models can usually be fitted, so mechanistic inferences from them are inevitably speculative. A peak in age-specific cancer incidence may reflect the elimination of a highly susceptible subgroup 6 but could be due to age-related decline in cellular turnover, a cohort effect or underdiagnosis in old age, and it seems unlikely that only 12% of the US population is susceptible to colon cancer. Nonetheless, the recognition that there are many individuals at much higher or lower risk than the population average drives the continuing effort to identify them and hence elucidate underlying genetic and environmental mechanisms, as illustrated by these and the other examples discussed by Aalen et al.
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Frailty may prove important legally as well as scientifically. A worker who develops lung cancer following exposure to an industrial carcinogen that causes a relative risk of 1.5 for lung cancer does not receive compensation under English law because on the balance of probabilities the carcinogen was not the cause. Compensation might however be awarded if it could be shown that without the exposure the cancer would have developed more slowly. The very large number of common inherited variants, each explaining a small fraction of polygenic variation in inherited cancer risk, would not be rate-limiting events if they arose as somatic mutations and would not be classified as driver mutations in a lung cancer. 7 However, some may slightly increase the rate at which the steps in carcinogenesis occur in the affected cell. If a subset of the large number of 'passenger' mutations were caused by the industrial carcinogen and accelerated the lung cancer's development by a few years, the law should change. The courts accept the concept of accelerated disease progression for chronic obstructive lung disease. The only difference is in the frailty models. At present the probability that the same individual would have developed lung cancer a few years later without the industrial exposure is meaningful but unmeasurable.
